5 Most Promising Biotech Stocks to Buy Now

2. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

On May 1, Morgan Stanley bumped up its price goal on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to $370 from $360. It maintained an Equal Weight rating on the stock.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reported first quarter 2026 financials, delivering global net product revenues of $1.036 billion, climbing 121% year over year. This was powered by total TTR revenues of $910 million that surged 153%. That momentum came largely from AMVUTTRA contributing $890 million, with ONPATTRO adding $20 million, together anchoring the TTR franchise.

M.D Chief Executive Officer of Alnylam, Yvonne Greenstreet, said in the company’s statement that the quarter marked “over $1 billion in quarterly product revenues for the first time.” She pointed to ongoing progress across Phase 3 and Phase 1 pipeline programs.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) reiterated its 2026 outlook, guiding for $4.9 billion to $5.3 billion in total net product revenues. It includes $4.4 billion to $4.7 billion from TTR products.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) develops and markets RNA interference-based therapeutics. The company is headquartered in Cambridge, MA.